Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harvard Bioscience (HBIO)
NASDAQ:HBIO
Holding HBIO?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.05Last Year’s EPS
$0.04Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -25.18%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Neutral
The earnings call reveals a company in transition, dealing with significant revenue declines and challenges in the APAC region, particularly China. However, there are positive signs with stabilization in the Americas and Europe, successful cost reductions, and promising new product introductions that could drive future growth.Company Guidance
During the third quarter earnings call for Harvard Biosciences, the company provided guidance indicating a challenging market environment with Q3 revenue at $22 million, a 13% decline compared to the previous year. Despite this, the company achieved a gross margin of 58.1%, close to their 60% target. The company reported an operating loss of $1.9 million on a GAAP basis but achieved an adjusted operating income of $800,000. Adjusted EBITDA was reported at $1.3 million, representing 6% of revenue. The company highlighted a significant operational milestone with the transition to a modern ERP system, expecting to reduce operating expenses by $1 million per quarter. Looking forward, HBIO anticipates Q4 revenue between $23 million and $26 million, with a full-year revenue guidance of $93 million to $96 million. They expect improvement in adjusted EBITDA margins to the mid-teens in Q4, supported by cost reductions and new product introductions. The company remains optimistic about stabilizing markets in the Americas and Europe and anticipates modest improvement in China and Asia Pacific.ERP System Integration
Successfully transitioned and merged all U.S. operations onto one modern ERP system, enabling significant improvement in both inventory and supply chain management.
Cost Reductions and Efficiency Improvements
Additional actions taken to reduce operating expenses by $1 million a quarter, expected to structurally optimize the business and enable self-funding from operations.
New Product Introductions
Commencement of new product shipments, including the SoHo family of telemetry devices and the Mesh MEA organoid platforms, expected to drive growth in upcoming quarters.
Stabilization in Americas and Europe
Revenue from the Americas and Europe showing signs of stabilization, with three sequential quarters of roughly flat revenue.
---
HBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $2.82 | $2.39 | -15.25% |
| Aug 08, 2024 | $2.79 | $3.12 | +11.83% |
| May 07, 2024 | $3.92 | $3.75 | -4.34% |
| Mar 07, 2024 | $4.11 | $4.51 | +9.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Harvard Bioscience (HBIO) report earnings?
Harvard Bioscience (HBIO) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Harvard Bioscience (HBIO) earnings time?
Harvard Bioscience (HBIO) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HBIO EPS forecast?
HBIO EPS forecast for the fiscal quarter 2024 (Q4) is $0.05.
---